CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine

被引：18

作者：

Capi, Matilde ^{[1
]}

De Angelis, Valerio ^{[2
]}

De Bernardini, Donatella ^{[1
]}

De Luca, Ottavia ^{[3
]}

Cipolla, Fabiola ^{[2
]}

Lionetto, Luana ^{[1
]}

Simmaco, Maurizio ^{[1
,3
,4
]}

Martelletti, Paolo ^{[2
]}

机构：

[1] St Andrea Univ Hosp, Mass Spectrometry Unit, Lab Clin Biochem, I-00185 Rome, Italy

[2] Sapienza Univ Rome, Dept Clin & Mol Med, I-00185 Rome, Italy

[3] St Andrea Univ Hosp, Adv Mol Diagnost Unit, Lab Clin Biochem, I-00185 Rome, Italy

[4] Sapienza Univ, Dept Neurosci Mental Hlth & Sensory Organs NESMOS, I-00185 Rome, Italy

来源：

JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 07期

关键词：

migraine; CGRP; therapy; gepants; ditans; antagonism; CGRP receptor; GENE-RELATED PEPTIDE; MONOCLONAL-ANTIBODIES; SAFETY PROFILE; LASMIDITAN;

D O I：

10.3390/jcm10071429

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Discovering that calcitonin-related peptide (CGRP) plays a key role in the complex pathophysiology of migraine has allowed us to make great strides in the development of new approaches for acute and preventive treatment. This evidence has led to the development of small molecules antagonist molecules of the CGRP receptor ("gepants") and of a new class of medications called "Ditans". This review presents the data from clinical trials reporting the efficacy, safety, and tolerability of the new drugs used in the treatment of migraines. Evidences show that therapeutic approaches targeted to CGRP have the potential to transform the clinical management of migraine, even though its appropriate place has yet to be determined with accuracy.

引用

页数：17

共 50 条

[11] Progress towards an orally bioavailable 5-HT1F receptor agonist.
Blanco, MJ
Benesh, DR
Mahadevan, S
Filla, SA
Hudziak, KJ
Kohlman, DT
Mathes, BM
Victor, F
Xu, YC
Ying, BP
Zhang, D
Cohen, MP
Zacherl, DP
Dickman, DK
Gough, WH
Johnson, KW
Nelson, DL
Nutter, SE
Phebus, LA
Van Belle, K
Wainscott, DB
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 227 : U55 - U55
[12] The Effect and Safety of 5-HT1F Receptor Agonist Lasmiditan on Migraine: A Systematic Review and Meta-Analysis
Gu, Ping
Chen, Cheng
Wu, Qian
Dong, Changhong
Wang, Teng
Wan, Qi
Dong, Xin
BIOMED RESEARCH INTERNATIONAL, 2021, 2021
[13] 5-HT1D-receptor antagonists for the treatment of migraine
Lloyd, A
DRUG DISCOVERY TODAY, 2000, 5 (11) : 530 - 530
[14] The selective 5-HT1F receptor agonist lasmiditan inhibits trigeminal nociceptive processing: Implications for migraine and cluster headache
Vila-Pueyo, Marta
Page, Keith
Murdock, Paul R.
Loraine, Howard J.
Woodrooffe, Amanda J.
Johnson, Kirk W.
Goadsby, Peter J.
Holland, Philip R.
BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (03) : 358 - 370
[15] CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment
Edvinsson, Lars
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (02) : 193 - 199
[16] Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine:: a randomised controlled trial
Goldstein, DJ
Roon, KI
Offen, WW
Ramadan, NM
Phebus, LA
Johnson, KW
Schaus, JM
Ferrari, MD
LANCET, 2001, 358 (9289): : 1230 - 1234
[17] The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials
Tfelt-Hansen, Peer C.
Olesen, Jes
JOURNAL OF HEADACHE AND PAIN, 2012, 13 (04): : 271 - 275
[18] The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials
Peer C. Tfelt-Hansen
Jes Olesen
The Journal of Headache and Pain, 2012, 13 : 271 - 275
[19] Targeting CGRP and 5-HT1F Receptors for the Acute Therapy of Migraine: A Literature Review
Moreno-Ajona, David
Chan, Calvin
Villar-Martinez, Maria Dolores
Goadsby, Peter J.
HEADACHE, 2019, 59 : 3 - 19
[20] Targeted 5-HT1F Therapies for Migraine
Vila-Pueyo, Marta
NEUROTHERAPEUTICS, 2018, 15 (02) : 291 - 303

← 1 2 3 4 5 →